drugset / Trial / NCT00273650

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

NCT00273650

Phase 2/3 Completed 30 enrolled University of California, San Francisco
RandomizedCrossoverTriple-blindTreatment

Summary

We will be testing a specific dietary supplement, methylcobalamin (vitamin B12). Follow-up assessments with our clinical team will take place over the 12-week study period so that we can record any changes in development. The main goal of this study is to determine if subcutaneous injections of vitamin B12 given every three days can positively affect behavior and development in children with autism. Hypothesis: Methylcobalamin injections will improve measures of executive function, speech, and socialization in children with autism, and will be associated with metabolic improvement.

Timeline

Start
2005-07
Primary completion
2009-06
Completion
2009-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator methylcobalamin Small molecule 64.5 ug/kg Subcutaneous